scholarly journals Acute Generalized Exanthematous Pustulosis Induced by Erlotinib (Tarceva) with Superimposed Staphylococcus aureus Skin Infection in a Pancreatic Cancer Patient: A Case Report

2012 ◽  
Vol 5 (2) ◽  
pp. 253-259 ◽  
Author(s):  
Egbert Liquete ◽  
Syed Ali ◽  
Revark Kammo ◽  
Moiz Ali ◽  
Fadi Alali ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Staphylococcus Aureus ◽  
Case Report ◽  
Cancer Patient ◽  
Skin Infection ◽  
Pancreatic Cancer Patient ◽  
Acute Generalized Exanthematous Pustulosis ◽  
Exanthematous Pustulosis

scholarly journals Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report

2019 ◽  
Vol 4 (1) ◽  
pp. 10-14
Author(s):  
Adam R. Wolfe ◽  
Rishi Jain ◽  
Timothy M. Pawlik ◽  
Jon Walker ◽  
Terence M. Williams
Keyword(s):  
Pancreatic Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Brca2 Mutation ◽  
Pancreatic Cancer Patient ◽  
Radiation Induced

scholarly journals Inflammatory Response to Exercise in a Pancreatic-cancer Patient: a Case Report

2016 ◽  
Vol 6 (4) ◽  
Author(s):  
Anna Pedrinolla ◽  
Luca Paolo Ardigo ◽  
Gian Luca Salvagno ◽  
Giovanni Li Volti ◽  
Elena Caveggion
Keyword(s):  
Pancreatic Cancer ◽  
Case Report ◽  
Inflammatory Response ◽  
Cancer Patient ◽  
Pancreatic Cancer Patient ◽  
Response To Exercise

scholarly journals Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine

2018 ◽  
Vol 67 (10) ◽  
pp. 1603-1609 ◽  
Author(s):  
Hiroaki Shima ◽  
Goro Kutomi ◽  
Fukino Satomi ◽  
Masafumi Imamura ◽  
Yasutoshi Kimura ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Peptide Vaccine ◽  
Pancreatic Cancer Patient ◽  
Term Survival ◽  
Long Term Survival

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report

2021 ◽  
pp. 1-7
Author(s):  
Janna-Lisa Velthaus ◽  
Peter Iglauer ◽  
Ronald Simon ◽  
Carsten Bokemeyer ◽  
Peter Bannas ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Point Mutation ◽  
Kinase Inhibitors ◽  
Point Mutations ◽  
Progression Free Survival ◽  
Pancreatic Cancer Patient ◽  
Targeted Treatment ◽  
Precision Oncology ◽  
Disease Stabilization

<b><i>Introduction:</i></b> The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack of development in precision oncology including immune oncology in this entity. Rearrangements of the proto-oncogene tyrosine protein kinase <i>ROS1</i> gene represent driver alterations found especially in lung cancer. Tyrosine kinase inhibitors (TKI) with activity against ROS1 including lorlatinib substantially improved the outcome of this patient population. Anecdotal evidence reports treatment of pancreatic cancer harboring <i>ROS1</i> fusions with ROS1 TKI, but data concerning treatment of patients with <i>ROS1</i> point mutations are lacking. <b><i>Case Presentation:</i></b> This case describes a pancreatic cancer patient harboring a <i>ROS1</i> point mutation that occurred without an underlying <i>ROS1</i> rearrangement and thus not in the resistance situation. The heavily pretreated patient showed a strong decrease of the tumor biomarkers (CA19-9 and CEA) and radiologically a durable stable disease to the targeted treatment with lorlatinib, thereby achieving a progression-free survival of 12 months. <b><i>Conclusion:</i></b> Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far undescribed <i>ROS1</i> point mutation without a concomitant <i>ROS1</i> rearrangement. Furthermore, they indicate that <i>ROS1</i> could be an oncogenic driver in pancreatic cancer. This subgroup could be eligible for targeted treatments, which may contribute to the urgently needed improvement in patient outcome.

Sign in / Sign up

Export Citation Format

Share Document